Healthia : Supplementary Investor Presentation

only
ASX ANNOUNCEMENT
2 March 2022
	SUPPLEMENTARY INVESTOR PRESENTATION

Healthia Limited (Healthia or the Company) attaches a further Investor Presentation (Supplementary Investor Presentation) usewhich is supplementary to its Investor Presentation lodged with the ASX on 28 February 2022 and named, "H1 FY22 Investor

Pr sentation" (Earlier Investor Presentation).

The only variations between the Supplementary Investor Presentation and the Earlier Investor Presentation are the inclusion of two references on page 3 to support Healthia's stated position as being the number one physiotherapy group in Australia and New Zealand, and on page 20 regarding Healthia's analysis of total addressable revenue and market share.

CONTACT

personalFor	Company		Company
	Company
	Wesley Coote	Chris Banks		Julia Murfitt
	Group CEO & Managing Director	CFO & Company Secretary		General Counsel & Company Secretary
	Tel: [phone]	Tel: [phone]		Tel: [phone]
	E: [e-mail]	E:[e-mail]		E:[e-mail]

-END-

ersonal use only

H122 RESULTS PRESENTATION

28 FEBRUARY 2022

Healthia Limited ACN 626 087 223

GLOSSARY

	Term	Definition
	Cash Conversion %	Calculated as EBITDA (pre-AASB16) divided by operating cash flow before finance, acquisition and tax costs.
	Clinic Class Shares	Clinic Class Shares are non-voting shares which entitle the holder to a share of any dividend declared, calculated on the performance of the clinic in which the Clinic Class Shares are
		issued. The Clinic Class Shares are designed to create alignment between the interests of clinicians and Healthia shareholders.
	EBIT(u)	Underlying EBIT reflects statutory EBIT as adjusted to reflect the Directors' assessment of the result for the ongoing business activities of the Consolidated Entity, in accordance with
		AICD/Finsia principles of recording underlying profit. EBIT(u) is presented on a pre-AASB16 basis. Underlying EBIT has not been audited.
	EBITDA(u)	Underlying EBITDA reflects statutory EBITDA as adjusted to reflect the Directors' assessment of the result for the ongoing business activities of the Consolidated Entity, in accordance
		with AICD/Finsia principles of recording underlying profit. EBITDA(u) is presented on a pre-AASB16 basis. Underlying EBITDA has not been audited.
	EBITDA(x)	Expectations for annualised portfolio run-rate at commencement of FY23. Presented pre-AASB16 and assuming no impacts from COVID.
	EPS(u)	Underlying basic earnings per shareas adjusted to reflect the Directors' assessment of the result for the ongoing business activities of the Consolidated Entity, in accordance with
only	AICD/Finsia principles of recording underlying results.
	H121	Half year period ended 31 December 2020.
	H122	Half year period ended 31 December 2021.
	H222	Half year period ended 30 June 2022.
	Leverage ratio	Calculated as (Debt:Adjusted EBITDA) in accordance with bank covenants. Note:
		- Adjusted EBITDA adjusts for the earnings contribution of recent acquisitions where the businesses have not been held for a 12-month period; and
		- AASB 16 'Leases' does not apply, and covenants are calculated as they were prior to the adoption of this accounting standard by the Consolidated Entity.
	NPAT - attributed to shareholders Net Profit After Tax attributable to shareholders (i.e after non-controlling interests).
use
	NPATA(u)	Underlying NPATA is a non-IFRS measure and equals net profit after income tax expense plus amortisation of customer list intangibles. Underlying profit reflects statutory profit as
		adjusted to reflect the Directors' assessment of the result for the ongoing business activities of the Consolidated Entity, in accordance with AICD/Finsia principles of recording underlying
		profit. Underlying NPATA has not been audited.
ersonal	Underlying NPBT is a non-IFRS measure and equals net profit before income tax expense plus amortisation of customer list intangibles. Underlying profit reflects statutory profit as
	NPBTA(u)
		adjusted to reflect the Directors' assessment of the result for the ongoing business activities of the Consolidated Entity, in accordance with AICD/Finsia principles of recording underlying
		profit. Underlying NPBTA has not been audited.
	Revenue(u)	Underlying Revenue reflects statutory revenue as adjusted to reflect the Directors' assessment of the result for the ongoing business activities of the Consolidated Entity, in accordance
		with AICD/Finsia principles of recording underlying results and includes adjustments for the impacts from COVID-19 for the Consolidated Entity. Underlying revenue has not been
		audited.
	Same Clinic Growth	Same Clinic growth represents revenue growth which has been calculated by excluding any closed businesses and businesses not held during the prior period.
	Tax(u)	Underlying tax. Calculated based on 30% corporate tax rate applied to NPBTA(u).
		2

DRAFT & INCOMPLETE

H1 FY22 - SUMMARY

 Revenue growth during H122 despite COVID lockdowns and outbreaks demonstrating the resilience of the Healthia business model.
 EBITDA(u) increased to $12.2 million, or by 11% on prior period (H121: $11.0 million).
only
	EBITDA(x) - Healthia expects to commence FY23 with an annualised portfolio of greater than $40.0 million (assuming no material impacts from COVID).
	Clinic Growth - $102.2 million of capital deployed to acquire 76 physiotherapy clinics, 3 optical stores and 1 podiatry clinic.

 During the period, Healthia positioned itself as the number one physiotherapy group1 in Australia and New Zealand through the strategic acquisition of the 63 Back In Motion physiotherapy clinics.

 Increase in finance facility from $70 million to $100 million, which provides significant headroom to continue the stated strategy of pursuing value accretive acquisition opportunities.

 Supporting our team - Healthia continued to support its team members during lockdown and made minimal rostering changes.

 Graduate Recruitment - Healthia has recruited 154 new graduate clinicians (FY21:64) who started in Feb 2022 and undertook the structured graduate induction
use
	training.
 2.0 cents per share dividend payment to be supported by a fully underwritten dividend reinvestment plan.
ersonal
	iOrthotics awarded a Government grant of $2.0 million to support research into designed led advanced manufacturing of smart orthotics for regional and remote

Australia.

1. This statement has been made by Healthia in reliance on supporting material from the IBISWorld report "Q8533 Physiotherapy Services in Australia", dated June 2021. In particular, the businesses of
two of the three companies being listed as "Major Companies" by IBISWorld are owned by Healthia Limited, being Back In Motion health group and The Physio Co. Healthia is also aware that its	3
physiotherapy portfolio owned is significantly larger than the third largest "Major Company" listed by IBISWorld, being Zenitas Healthcare Limited through the acquisition announcement released by APM
Human Services International Limited which acquired the physiotherapy portfolio of Zenitas Healthcare Limited (APM Human Services International Limited ASX Announcement, 3 December 2021, "APM
to acquire Lifecare, On tract to deliver FY22 Forecasts").

DRAFT & INCOMPLETE

H1 FY22 DEMONSTRATES RESILIENT BUSINESS MODEL

only	REVENUE	EBITDA(u)	EBITDA(x)	•	Revenue growth during H122 despite COVID lockdowns,
$93.0m	$12.2m	>$40m		restrictions and outbreaks, demonstrating the resilience
	*	•	of the Healthia businesses.
51.3% increase	11.1% increase	*Assumes nil COVID impacts	COVID impacted profitability as Healthia ensured
	minimal changes to its team members hours/ pays
110.1% increase	111.9% increase			occurred during lockdown and restriction periods.
	• Continued payment of dividends, supported by a fully
NPATA(u)	EPS(u)	DIVIDEND		underwritten dividend reinvestment plan.
use	•	Portfolio growth continued during H122, including the
$4.6m	4.27 cps	2.0 cps		acquisition of the 63 Back In Motion	physiotherapy
	clinics, increasing EBITDA(x) to over $40 million.
2.5% decrease	37.8% decrease	2.0 cps in H121	•	Graduate recruitment to support vacancies, continued
	growth and other COVID related workforce impacts.
90.6% increase	10.9% increase
ersonal		LEVERAGE RATIO	GRAD RECRUITMENT		NO. CLINICS
CAPITAL DEPLOYED		vs H121
	$102m	1.89x	154		292	vs H120
	Target +$20m p.a.	Down from 1.94x @ 30 Jun	Up from 64 in FY21		38% increase from 30 Jun
Note: the numbers above are unaudited and reflects the underlying results of the Group, pre-AASB16. For a reconciliation between underlying and statutory results, please see the Appendices of this presentation	4